References

1. Epstein DL. In: Epstein DL, Allingham R, Schuman JS, eds. Chandler and Grant's Glaucoma. 4th ed. Philadelphia: Williams & Wilkins; 1997.

2. Smith J, Wandel T. Rationale for the one-eye therapeutic trial. Ann Ophthalmol. 1986;18:8.

3. Grant WM, Burke JF Jr. Why do some people go blind from glaucoma? Ophthalmology. 1982;89:991-998.

4. Ritch R, Shields MB, Krupin T. Chronic open-angle glaucoma: treatment overview. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas: Glaucoma Therapy. Boston: Mosby; 1996:1513.

5. Doi LM, Melo LA Jr, Prata JA Jr. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial. Br J Ophthalmol. 2005;89(5):547-549.

6. Nardin G, et al. Activity of the topical CAI MK-507 bid when added to timolol bid. Invest Ophthalmol Vis Sci. 1991;32(suppl):989.

7. Serle JB, Podos SM, Abundo GP, et al. The effect of brimonidine tartrate in glaucoma patients on maximal medical therapy. Invest Ophthalmol Vis Sci. 1993;34(suppl): 1137.

Racz P, Ruzsonyi MR, Nagy ZT, Gaygi Z, Bito LZ. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996;114(3):268-273. Alm A, Widengard I, Kjellgren D, Soderstrom M, Fristrom B, Heijl A, Stjerschantz J. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79(1):12-16.

Villumsen J, Alm A. Effect of the prostaglandin F2alpha analogue PhXA41 in eyes treated with pilocarpine and timolol. Invest Ophthalmol Vis Sci. 1992;33(suppl): 1248.

Fristrom B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111(5):662-665.

Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzola-mide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin. 2005;21(4):503-508.

Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and bri-monidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28(4):552-559. O'Connor DJ, Martone if, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol. 2002;133:836-837. Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006;113(3):442-445. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392-399.

Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242-250. Kharod BV, Johnson PB, Nesti HA, Rhee DJ. Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients. J Glaucoma. 2006; 15(3):244-247.

Rivers PH. Compliance aids—do they work? Drugs Aging. 1992;2(2):103-111. Boden C, Sit A, Weinreb RN. Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops. J Glaucoma. 2006;15(1):30-34. Allingham RR. Management of highly elevated intraocular pressure. In: Epstein DL, Allingham RR, Schuman JS, eds. Chandler and Grant's Glaucoma. 4th ed. Baltimore, Md: Williams & Wilkins; 1997:177-180.

Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol. 1995;120(6):718-731. Stewart WC, Sine CS, LoPresto C. Surgical vs. medical management of chronic open-angle glaucoma. Am J Ophthalmol. 1996;122:767-774.

Committee on Ophthalmic Procedure Assessment. Laser trabeculoplasty for primary open-angle glaucoma. Ophthalmology. 1996;103:1706-1712.

25. Weinreb RN, Tsai CS. Laser trabeculoplasty. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas: Glaucoma Therapy. 2nd ed. Boston: Mosby; 1996:1575-1590.

26. Shingleton BJ, Richter CU, Bellows AR, et al. Long-term efficacy of argon laser trabeculoplasty. Ophthalmology. 1987; 94:1513-1518.

27. Schwartz AL, Whitten ME, Bleiman B, Martin D. Argon laser trabecular surgery in uncontrolled phakic open angle glaucoma. Ophthalmology. 1981;88:203-212.

28. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 2. Results of argon laser trabeculoplasty versus topical medications. Ophthalmology. 1990;97: 1403-1413.

29. Thomas JV, Simmons RJ, Belcher CD. Argon laser trabeculoplasty in the pre-surgical glaucoma patient. Ophthalmology. 1982;89:187-197.

30. Schwartz AL, Love DC, Schwartz MA. Long-term follow-up of argon laser trabecu-loplasty for uncontrolled open angle glaucoma. Arch Ophthalmol. 1985;103:1482-1484.

31. Reiss GR, Wilensky JT, Higginbotham EJ. Laser trabeculoplasty. Surv Ophthalmol. 1991;35:407-428.

32. Thomas JV, Simmons RJ, Belcher CD. Complications of argon laser trabeculoplasty. Glaucoma. 1982;4:50.

33. Krupin T, Stank T, Feitl ME. Apraclonidine pretreatment decreases the acute intraocular pressure rise after laser trabeculoplasty or iridotomy. J Glaucoma. 1992;1:79-86.

34. The Brimonidine-ALT Study Group. Effect of brimonidine 0.5% on intraocular pressure spikes following 360 argon laser trabeculoplasty. Ophthalmol Surg Lasers. 1995;26:404-409.

35. Latina MA, Sibayan SA, Shin DH, et al. Q-switched 532-nm Nd:YAG laser trabecu-loplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology. 1998;105:2082-2088.

36. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment of open-angle glaucoma. Arch Ophthalmol. 2003;121:957-960.

37. Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology. 2004;111:1853-1859.

38. Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. Br J Ophthalmol. 1999;83: 18-722.

39. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001;108:773-779.

This page intentionally left blank

Reducing Blood Pressure Naturally

Reducing Blood Pressure Naturally

Do You Suffer From High Blood Pressure? Do You Feel Like This Silent Killer Might Be Stalking You? Have you been diagnosed or pre-hypertension and hypertension? Then JOIN THE CROWD Nearly 1 in 3 adults in the United States suffer from High Blood Pressure and only 1 in 3 adults are actually aware that they have it.

Get My Free Ebook


Post a comment